Marco Mor Selected Research

Marco Mor Research Topics

Disease

26	Neoplasms (Cancer) 02/2022 - 11/2011
16	Pain (Aches) 12/2021 - 06/2005
9	Inflammation (Inflammations) 12/2021 - 12/2009
8	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 12/2021 - 03/2010
6	Body Weight (Weight, Body) 01/2020 - 08/2006
6	Lung Neoplasms (Lung Cancer) 01/2019 - 02/2008
3	Sleep Initiation and Maintenance Disorders (Insomnia) 07/2015 - 01/2008
2	Multiple Myeloma 01/2020 - 01/2016
2	Osteoarthritis 01/2020 - 01/2015
2	Neoplasm Metastasis (Metastasis) 12/2018 - 01/2016
2	Necrosis 09/2017 - 01/2003
2	Prostatic Neoplasms (Prostate Cancer) 10/2013 - 06/2012
2	Carcinogenesis 10/2013 - 06/2012
2	Hyperalgesia 09/2013 - 03/2013
2	Catalepsy 02/2013 - 01/2006
2	Sleep Wake Disorders 12/2011 - 01/2008
1	Chronic Pain 10/2021
1	Waldenstrom Macroglobulinemia (Macroglobulinemia) 01/2021
1	Hematologic Neoplasms (Hematological Malignancy) 01/2021
1	Glioblastoma (Glioblastoma Multiforme) 02/2020
1	Joint Diseases (Joint Disease) 01/2020
1	Anhedonia 01/2020
1	Carcinoma (Carcinomatosis) 12/2019
1	Monosomy 09/2019
1	Uveal melanoma 09/2019
1	Ovarian Neoplasms (Ovarian Cancer) 01/2018
1	Glaucoma 01/2018
1	Melanoma (Melanoma, Malignant) 09/2017
1	Breast Neoplasms (Breast Cancer) 09/2017
1	Pathologic Processes 05/2016
1	Neurodegenerative Diseases (Neurodegenerative Disease) 01/2016

Drug/Important Bio-Agent (IBA)

6	fatty-acid amide hydrolase (fatty acid amide hydrolase)IBA 01/2018 - 09/2005
5	AcidsIBA 10/2021 - 12/2009
5	Fibroblast Growth Factors (Fibroblast Growth Factor)IBA 01/2021 - 08/2015
5	Tyrosine Kinase InhibitorsIBA 01/2020 - 02/2008
5	Gefitinib (Iressa)FDA Link 01/2019 - 07/2010
5	ErbB Receptors (EGF Receptor)IBA 03/2015 - 07/2010
4	N-acylethanolaminesIBA 10/2021 - 12/2009
4	EnzymesIBA 10/2021 - 11/2011
4	Peroxisome Proliferator-Activated Receptors (PPAR)IBA 10/2021 - 03/2013
4	amidaseIBA 10/2021 - 12/2009
4	Fibroblast Growth Factor Receptors (Fibroblast Growth Factor Receptor)IBA 01/2021 - 08/2015
4	heparanaseIBA 12/2020 - 01/2016
4	EndocannabinoidsIBA 05/2016 - 07/2007
4	LigandsIBA 01/2016 - 06/2012
4	anandamide (arachidonylethanolamide)IBA 12/2015 - 01/2006
3	Proteins (Proteins, Gene)FDA Link 02/2022 - 01/2013
3	LipidsIBA 10/2021 - 08/2006
3	Pharmaceutical PreparationsIBA 02/2020 - 07/2007
3	EphrinsIBA 02/2020 - 06/2012
3	CannabinoidsIBA 01/2020 - 01/2006
3	SolutionsIBA 01/2019 - 09/2009
3	Biological ProductsIBA 01/2018 - 11/2015
3	Melatonin Receptors (Melatonin Receptor)IBA 01/2018 - 01/2008
3	ramelteon (Rozerem)FDA Link 07/2015 - 01/2008
3	Analgesics (Analgesic Drugs)IBA 11/2011 - 07/2007
3	cyclohexyl carbamic acid 3'-carbamoylbiphenyl-3-yl ester (URB597)IBA 09/2009 - 07/2007
2	AntioxidantsIBA 01/2020 - 09/2017
2	URB937IBA 12/2019 - 10/2010
2	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2018 - 08/2015
2	Lithocholic AcidIBA 01/2016 - 04/2013
2	CarbamatesIBA 01/2016 - 09/2009
2	Sucrose (Saccharose)IBA 11/2015 - 11/2007
2	EphA2 ReceptorIBA 09/2015 - 06/2012
2	palmidrolIBA 08/2015 - 12/2009
2	oleoylethanolamideIBA 08/2015 - 08/2006
2	Adenosine Triphosphate (ATP)IBA 03/2015 - 03/2010
2	cholanic acidIBA 10/2013 - 06/2012
2	5-phenylpentyl N- ((2S,3R)- 2- methyl- 4- oxo- oxetan- 3- yl)carbamateIBA 09/2013 - 03/2013
2	Phosphotransferases (Kinase)IBA 01/2013 - 11/2011
2	Protein-Tyrosine Kinases (Tyrosine Kinase)IBA 03/2012 - 07/2010
2	Cannabinoid Receptors (Cannabinoid Receptor)IBA 11/2011 - 10/2010
2	PPAR alphaIBA 12/2009 - 08/2006
1	Transcription Factors (Transcription Factor)IBA 02/2022
1	osimertinibIBA 12/2021
1	Therapeutic UsesIBA 12/2021
1	CatalaseIBA 01/2020
1	Bortezomib (Velcade)FDA Link 01/2020
1	Iodoacetic AcidIBA 01/2020
1	CytokinesIBA 01/2020
1	Vitamin E FDA LinkGeneric 01/2020
1	CorticosteroneIBA 01/2020
1	erdafitinibIBA 12/2019
1	Cysteine (L-Cysteine)FDA Link 01/2019
1	chloroacetamideIBA 01/2019
1	Thymidylate SynthaseIBA 01/2018
1	Peptides (Polypeptides)IBA 01/2018
1	Proline (L-Proline)FDA Link 01/2018
1	MelatoninIBA 09/2017
1	sulforaphaneIBA 07/2016
1	Serine (L-Serine)FDA Link 05/2016
1	Monoacylglycerol LipasesIBA 05/2016
1	HydrolasesIBA 05/2016
1	AnticoagulantsIBA 01/2016
1	SteroidsIBA 01/2016
1	roneparstatIBA 01/2016
1	SST 0001IBA 01/2016

Therapy/Procedure

9	Therapeutics 10/2021 - 10/2010
2	Oral Administration 12/2019 - 07/2007
2	Topical Administration 09/2013 - 03/2013